# Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

> **NCT07407452** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Cancers

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab (QL1706)Injection
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Olaparib
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07407452
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407452, "Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07407452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*